Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Department of Internal Medicine, Division of Haematology-Oncology, American University of Beirut Medical Centre, Cairo Street, PO Box 11-0236, Riad El Solh, Beirut, 1107 2020, Lebanon.
Ann Hematol. 2021 May;100(5):1115-1122. doi: 10.1007/s00277-021-04441-y. Epub 2021 Feb 1.
COVID-19 pandemic has imposed worldwide challenge and has significantly affected transfusion medicine. Shortage in blood products along with concerns regarding the safety of blood products have emerged. Measures to overcome these challenges have been implemented in order to decrease the demand on blood products and to encourage blood donations while taking full precautions to minimize risk of COVID-19 transmission mainly at blood banks and medical centers. Several countries have been successful in facing these new challenges. In addition, the role of plasma therapy in the treatment of COVID-19 patients, especially in severe cases, has been proposed and current studies are being conducted to determine its efficacy. Other therapeutic options are currently being explored. So far, the use of convalescent plasma is considered a promising rescue treatment to be looked at.
新冠疫情大流行带来了全球性挑战，对输血医学产生了重大影响。血液制品短缺以及对血液制品安全性的担忧已经出现。为了降低对血液制品的需求，并在充分采取预防措施以最大程度降低新冠病毒传播风险（主要在血库和医疗中心）的同时鼓励献血，已经实施了一些措施来应对这些挑战。一些国家已经成功应对了这些新挑战。此外，还提出了血浆疗法在治疗 COVID-19 患者（尤其是重症患者）中的作用，目前正在进行研究以确定其疗效。目前还在探索其他治疗选择。到目前为止，使用恢复期血浆被认为是一种有前途的治疗方法。
